GHK-Cu (Copper Tripeptide-1)
Overview
GHK-Cu is a copper(II)-binding tripeptide — glycyl-L-histidyl-L-lysine bound to a single copper ion — that occurs naturally in human plasma, saliva and other body fluids. It ranks among the most thoroughly documented cosmetic peptides, appearing across research on collagen synthesis, dermal-matrix remodeling, antioxidant defence, angiogenesis and wound repair. Its defining feature is a dual character: it both carries copper to copper-dependent enzymes and acts in its own right as a matrix-signalling peptide (a matrikine).
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 89030-95-5 (GHK-Cu) · 49557-75-7 (GHK, free peptide) |
| INCI name | Copper Tripeptide-1 |
| Amino-acid sequence | H-Gly-His-Lys-OH |
| One-letter code | GHK |
| Molecular formula | C₁₄H₂₄N₆O₄·Cu (copper complex) |
| Molecular weight (GHK) | 340.42 g/mol (free tripeptide) |
| Molecular weight (GHK-Cu) | ≈ 403.9 g/mol (copper complex) |
| Copper content | ≈ 13.6% w/w |
| Purity (HPLC) | ≥ 98% |
| Appearance | Blue to blue-violet lyophilized powder |
- Class
- Copper-binding signal peptide (matrikine)
- Natural source
- Human plasma, saliva, urine
- Research status
- Extensive preclinical + human studies
- Typical route
- Topical (cosmetic research)
- Plasma half-life (GHK)
- ~15 min (free peptide)
- Key feature
- Copper delivery + matrix signalling
Mechanism of Action
GHK-Cu is studied as both a copper ionophore and a signalling peptide, so its reported activity is usually described as several overlapping pathways rather than a single receptor event. The tripeptide holds copper(II) in a stable square-planar geometry and can hand that copper to copper-dependent enzymes, while the peptide backbone is investigated for direct effects on fibroblast gene expression.
| Pathway | Research description |
|---|---|
| Collagen & ECM | Studied for upregulation of type I and type III collagen, decorin and glycosaminoglycan synthesis in dermal-fibroblast models, often discussed alongside TGF-β signalling. |
| Copper transport | Investigated as a carrier that delivers Cu²⁺ to enzymes such as Cu/Zn-superoxide dismutase, lysyl oxidase and cytochrome c oxidase. |
| Antioxidant support | Referenced in research on antioxidant-enzyme activity and reduction of reactive-oxygen species in skin-cell models. |
| Angiogenesis | Associated in tissue-remodeling models with increased expression of angiogenic factors such as VEGF and bFGF. |
| Anti-inflammatory tone | Explored in relation to inflammatory-signalling markers in repair models. |
| Tissue regeneration | Widely cited for keratinocyte migration, granulation-tissue formation and re-epithelialization in wound-healing research. |
Tissue-specific effects reported in the literature (research context, not product claims):
| Tissue | Studied mechanism | Reported direction |
|---|---|---|
| Dermis | Fibroblast activity + collagen I/III synthesis | Increased dermal density in models |
| Epidermis | Keratinocyte migration and differentiation | Faster experimental wound closure |
| Vasculature | Angiogenic signalling (VEGF / bFGF) | Enhanced tissue perfusion in models |
| Scar tissue | Modulation of the TGF-β1 / TGF-β3 balance | Altered scar remodeling in models |
Pharmacology
| Parameter | Value |
|---|---|
| logP | −2.5 (hydrophilic) |
| pKa | ≈ 6.8 (imidazole), 10.5 (ε-amino), 3.2 (α-carboxyl) |
| Copper-binding affinity (Kd) | ≈ 2.5 × 10⁻¹⁶ M (very high) |
| Topical bioavailability | ~1–3% unassisted; higher with liposomal / penetration-enhanced systems |
| Protein binding | High (albumin, transcuprein) |
| Metabolism | Proteolytic cleavage by plasma and tissue peptidases |
| Elimination | Renal (peptide fragments); copper via biliary route |
Research Evidence
GHK-Cu is one of the most frequently referenced copper peptides in cosmetic and dermatological literature, with both cell/tissue (preclinical) and human (clinical) studies. The directions and study types below summarise where the peptide appears in published work; they describe research contexts, not guaranteed outcomes.
Collagen & dermal matrix
Central to research on collagen synthesis, glycosaminoglycan production and dermal-matrix density in fibroblast and skin-explant models.
Wound healing & repair
Extensively studied for re-epithelialization, granulation-tissue formation and angiogenesis in experimental wound models.
Antioxidant & photodamage
Investigated in oxidative-stress and UV-exposure models in connection with antioxidant-enzyme activity.
Hair & scalp
Examined in dermal-papilla and hair-follicle models in the context of follicular signalling.
Preclinical research — representative models and what they investigate:
| Model | Research focus | Reference |
|---|---|---|
| Human dermal fibroblasts | Type I / III collagen synthesis | Maquart FX, et al. (1993) |
| Fibroblast cultures | Sulfated glycosaminoglycan synthesis | Wegrowski Y, et al. (1992) |
| Human keratinocytes | Cell growth, morphogenesis and migration | Siméon A, et al. (2000) |
| Skin explants / wound models | Re-epithelialization and angiogenesis | Pickart L, Margolina A (review) |
Clinical research — the types of human study in which the ingredient is examined:
| Study type | Endpoints studied | Reference |
|---|---|---|
| Topical copper-tripeptide cream | Wound healing and skin recovery | Abdulghani AA, et al. (2008) |
| Facial photoaging formulations | Fine lines, skin density and firmness | Pickart L, Margolina A (review) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Stimulates type I/III collagen and glycosaminoglycan synthesis | human dermal fibroblasts | Maquart FX et al., 1993; Wegrowski Y et al., 1992 |
| Promotes keratinocyte migration and wound repair | keratinocyte / skin models | Siméon A et al., 2000 |
| Antioxidant-enzyme support and copper delivery | oxidative-stress models | Pickart L, Margolina A (review) |
For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.
Formulation & Dosing Reference
| Parameter | Value |
|---|---|
| Typical topical concentration | 0.1–3.0% (w/w) |
| Common working range | 0.5–2.0% |
| Solubility in water | ≥ 50 mg/mL (clear blue solution) |
| Solubility in ethanol | Insoluble |
| Recommended formulation pH | 5.0–7.0 (copper binding best preserved near 5.5) |
| Storage (powder) | 2–8°C, or −20°C long-term; sealed, dry, protected from light |
- Avoid strong chelators (EDTA, citrate) and reducing agents such as ascorbic acid, which can strip or reduce the bound copper.
- Compatible with glycerin, propylene glycol, hyaluronic acid and standard oil-in-water emulsions.
Safety Profile
Safety data below refer to published toxicology and cosmetic-ingredient assessments of the ingredient itself and are provided for formulation research reference.
| Assessment | Reported result |
|---|---|
| Acute oral toxicity (rat) | LD50 > 2000 mg/kg |
| Dermal irritation (rabbit) | Non-irritant at 5% |
| Ocular irritation (rabbit) | Mild, transient at concentrated solution |
| Skin sensitization (GPMT) | Non-sensitizing |
| Mutagenicity (Ames) | Negative |
| INCI status | Approved cosmetic ingredient (Copper Tripeptide-1) |
Physicochemical Properties
| Property | Value |
|---|---|
| Appearance | Blue to blue-violet lyophilized powder |
| Solubility in water | > 50 mg/mL (clear blue solution) |
| Solubility in DMSO | 10–20 mg/mL |
| Melting point | > 200°C (decomposition) |
| pH (1% aqueous) | 5.5–6.5 |
| Copper coordination | Square-planar Cu(II) complex |
| UV-Vis λmax | ≈ 610 nm (d–d transition, the blue colour) |
| Light sensitivity | Moderate — store in the dark |
Synthesis & Manufacturing
GHK-Cu is produced by solid-phase peptide synthesis (SPPS) of the GHK tripeptide, followed by controlled complexation with a copper(II) salt. The key manufacturing parameters below are typical for research-grade material.
| Step | Detail |
|---|---|
| Strategy | Solid-phase peptide synthesis, Fmoc/tBu chemistry |
| Resin | Wang resin (C-terminal acid) |
| Coupling | HATU / HBTU with DIPEA |
| Deprotection | 20% piperidine in DMF |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative reversed-phase HPLC (C18, TFA/ACN gradient) |
| Copper complexation | Copper(II) acetate, aqueous, pH ≈ 5.5 |
- Copper(II) acetate is preferred over sulfate or chloride for cleaner complexation and easier purification.
- Complexation pH is critical: below ~4.0 the histidine imidazole cannot coordinate copper; above ~7.0 copper hydroxide can precipitate.
- The blue-violet colour of the finished powder confirms correct square-planar Cu(II) coordination.
Analytical Methods
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| ESI-MS (positive mode) | Identity / mass confirmation | m/z consistent with GHK and the Cu complex |
| ICP-MS | Copper content | ≈ 13–14% w/w |
| UV-Vis (λmax 610 nm) | Copper coordination | Characteristic d–d transition band |
| CD spectroscopy | Cu(II) geometry | Consistent with a square-planar complex |
| Amino-acid analysis | Composition | Gly : His : Lys = 1 : 1 : 1 |
| Karl Fischer | Water content | < 5% |
| TGA | Thermal decomposition onset | > 200°C |
Representative RP-HPLC purity method:
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 20–40% B over ~20 min · Flow rate: 1.0 mL/min
- Detection: UV 214 nm (peptide bond) together with 610 nm (Cu(II) d–d band)
- Dual-wavelength detection confirms the peptide and the intact copper complex at the same time.
Stability Data
Representative stability behaviour under common storage and formulation conditions. The lyophilized powder is robust; solution stability depends on temperature and pH, and the copper complex is the part most sensitive to strong chelators and light.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized powder, 2–8°C, dark | ≥ 24 months | No significant degradation |
| Lyophilized powder, 25°C, dark | ≥ 12 months | Minimal degradation |
| Aqueous solution, pH 5.5, 4°C, dark | ≈ 7 days | Minor; copper retained |
| Aqueous solution, pH 5.5, 25°C | ≈ 48 h | Minor; copper retained |
| Aqueous solution, pH 5.5, 40°C | Hours | Copper begins to dissociate |
| Formulated cream / emulsion, 25°C | 12 months | Peptide and copper largely retained |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable |
- Copper binding is very strong, but the complex dissociates below pH ≈ 4.0 or with strong chelators such as EDTA and citrate.
- The copper chromophore is moderately light-sensitive — store in opaque containers.
- In formulation, avoid EDTA, citric acid and ascorbic acid (which can reduce Cu²⁺); the peptide is compatible with glycerin, propylene glycol, hyaluronic acid and standard oil-in-water emulsions.
Selected References
Representative peer-reviewed literature on GHK and GHK-Cu. Listed for research reference; individual findings are not restated here as product claims.
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition.
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide–copper complex GHK-Cu. FEBS Letters, 1993.
- Wegrowski Y, et al. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide–copper complex GHK-Cu. Biochemical Journal, 1992.
- Siméon A, et al. Effects of glycyl-histidyl-lysine and its copper complex on human keratinocytes. Journal of Investigative Dermatology, 2000.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; copper content verifiable by ICP-MS
- Research samples through to bulk, with worldwide delivery
- Custom packaging and related copper peptides on request
Need GHK-Cu — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
